Isothermal titration calorimetry determination of thermodynamics of binding of cocaine and its metabolites to humanized h2E2 anti-cocaine mAb

Terence L. Kirley 1, Andrew B. Norman

Department of Pharmacology and Systems Physiology, College of Medicine, University of Cincinnati, 231 Albert Sabin Way, Cincinnati, OH, 45267-0575, USA

ARTICLE INFO

Keywords:
- Monoclonal antibody
- Cocaine and metabolite binding
- Isothermal titration calorimetry
- Thermodynamics
- Ligand affinity

ABSTRACT

We analyzed the thermodynamics of binding of cocaine and several cocaine metabolites to a humanized anti-cocaine mAb (h2E2), which is under development for the treatment of cocaine use disorders, using isothermal titration calorimetry. The calculated equilibrium dissociation (binding) constants were consistent with previous findings using other methods. All three ligands that display high affinity (nM) binding to the mAb (cocaine, cocaethylene, and benzoylecgonine) displayed similar enthalpically driven binding with substantial enthalpy-entropy compensation. The increased affinity of the cocaethylene metabolite compared to cocaine and benzoylecgonine is mostly attributable to a substantially less negative entropic binding component for cocaethylene, resulting in a more favorable binding energy, and thus, a higher affinity. The much lower affinity cocaine metabolites, norcocaine and eocgonine methyl ester, have much lower binding enthalpies than the high affinity ligands, and in contrast to the three high affinity ligands, have favorable (positive) entropic thermodynamic components of binding. Surprisingly, approximately 3.7 molecules of norcocaine are bound per mAb Fab site, as determined by isothermal titration calorimetry. This is in contrast to the three high affinity ligands, which bound with the expected stoichiometry of one drug molecule bound per one mAb Fab site. The results are discussed in relation to the previously published Fab:benzoylecgonine crystal structure for this h2E2 mAb, and compared to the isothermal titration calorimetry results published previously using an unrelated anti-cocaine mAb, mAb08.

1. Introduction

As a therapy for cocaine use disorders, we have developed a high affinity anti-cocaine mAb, named h2E2, which also binds the pharmacologically active metabolite of cocaine, cocaethylene (CE), and the inactive metabolite, benzoylecgonine (BE), with high (nM) affinity [1–3]. As part of the characterization of this potential therapeutic antibody, we developed several assays to measure and assess the binding of cocaine and several cocaine metabolites to this h2E2 anti-cocaine mAb and its antibody fragments. Techniques utilized included quenching of intrinsic tyrosine and tryptophan mAb fluorescence [4] and differential scanning fluorimetry (DSF) using extrinsic fluorescent dyes [5]. We also used the fluorescent DASPMI rotor dye to assess high affinity cocaine and cocaine metabolite mAb binding by monitoring changes in both DASPMI absorbance [6] and fluorescence [7] upon ligand binding. In addition, using non-reducing SDS-PAGE, we demonstrated cocaine (ligand-induced) stabilization of the ligand binding protein domains of the intact mAb and its fragments [8], as well as mAb Fab fragment sub-domain ligand-induced stabilization [9]. Recently, we demonstrated that oxidation of tryptophan residues located in the h2E2 mAb drug binding site abolished high affinity binding [10].

In addition, we determined the structure of the h2E2 mAb Fab fragment, both in the presence and absence of co-crystallized benzoylecgonine (BE) ligand [11]. The crystal structure obtained was consistent with previous data concerning the involvement of multiple tyrosine and tryptophan residues in the cocaine binding pocket. However, the structure containing co-crystallized benzoylecgonine did not explain the previously noted differences in the mAb affinities (Kds) for the three high affinity ligands (CE, cocaine, and BE), because the carbohydrate group on the co-crystallized BE molecule was shown to have no direct contacts with any amino acid residues in the mAb Fab binding site. Thus, the molecular extensions (i.e., esterifications) of this carbohydrate group which differentiate cocaine (a methyl ester) and cocaethylene (CE, an ethyl ester) from BE, are also predicted by the BE-mAb crystal structure to have no interactions with the Fab binding site, and therefore should

* Corresponding author.
E-mail address: terry.kirley@uc.edu (T.L. Kirley).
not result in the experimentally observed increases in ligand affinities (decreased Kds) for the cocaine and CE ligands, relative to BE. However, we recently hypothesized that cocaine and cocaethylene may have slightly higher binding affinities to this h2E2 mAb due to additional contacts of their esterified carboxylates with a specific tyrosine residue located near the benzoylecgonine binding site on the mAb light chain (contacts which are not seen in the BE-mAb crystal). This was based on the observation that nitration of a specific tyrosine residue located near the benzoylecgonine binding site on the mAb light chain differentially affected the binding affinities of the three high affinity ligands, cocaine, cocaethylene, and benzoylecgonine [12].

Isothermal titration calorimetry (ITC) has not been used routinely to monitor the binding of antigens to antibodies, since most experimental and therapeutic mAbs bind large protein antigens rather than small molecules like cocaine or other drugs, making ITC thermodynamic binding measurements involving antibodies directed against large biomolecule antigens problematic. Nonetheless, one previous study examined the binding of methamphetamine to the antibody developed for its therapeutic treatment of methamphetamine abuse, using isothermal titration calorimetry (ITC) [13]. In addition, ITC was used to characterize the binding of cocaine to another anti-cocaine mAb (called mAb08 [14]). This mAb08 binds cocaine, BE, and CE with similar nM affinities as observed for the h2E2 mAb, however, the mAb08 anti-cocaine mAb binds cocaine with the highest affinity, followed by BE and then CE [14], in contrast to our anti-cocaine mAb, h2E2, which binds CE with the highest affinity, followed by cocaine, and then BE. This suggests a different mode of antigen/drug binding to the two mAbs, which could lead to different contributions of enthalpic and entropic components driving the drug binding affinities for the two anti-cocaine mAbs. Thus, in the present study we determined the thermodynamic components of binding of cocaine and cocaine metabolites to the h2E2 mAb and compared these results with previous findings using the mAb08 anti-cocaine mAb. In addition, we attempted to interpret the h2E2 mAb ITC binding thermodynamics to understand the reason for the rank order of h2E2 mAb ligand affinities for cocaine, CE, and BE, in light of the crystal structure of the Fab fragment of the h2E2 mAb determined with bound BE [11].

2. Materials and methods

2.1. Materials

The generation, production, and purification of the h2E2 anti-cocaine monoclonal antibody by the manufacturer, Catalent, was previously described [3]. The purity of this h2E2 mAb is estimated to be at least 98% by SDS-PAGE, with no other proteins detectable. Fab fragments of this mAb were generated by Endo-Lys-C digestion, and purified as previously described [4]. 10 mM ligand stock solutions of cocaine and cocaine metabolite ligands were made from solids as described [1]. Intact h2E2 mAb, Fab fragment, and the Fc fragment of h2E2 mAb were extensively dialyzed at 4 °C versus PBS buffer, diluted from a PBS buffer concentrate (10X) purchased from Cambrex (Bio-Whittaker, without calcium or magnesium, catalog number 17-517Q), prior to ITC analysis.

2.2. Methods

All isothermal titration calorimetry (ITC) experiments were performed at 20 °C using a MicroCal VP-ITC instrument. Twenty 14 µL injections of titrant (cocaine or cocaine metabolite) were performed for each experiment, adding to the 1.4227 ml cell sample containing h2E2 mAb or h2E2 Fab fragment or PBS buffer only, with all protein samples and ligand titrants dissolved in 0.22 µm filtered PBS buffer. The ITC sample cell was stirred at 320 rpm, and there was a delay of 240 s between each injection of ligand. Thermograms obtained by injection of the respective ligands into the buffer alone were subtracted from the mAb ITC data before fitting the corrected data to obtain the parameters reported in the Table. The data were analyzed and fit using the one binding site model incorporated into the Origin 7.0 software supplied with the instrument. Kd (dissociation constant) values were calculated by taking the reciprocal of the Origin best fitted ITC K (association constant) values, and ΔG values reported in the Table were calculated using the Origin fitted values of ΔH and program calculated values of ΔS, and the Gibbs free energy equation, ΔG = ΔH − TΔS. Approximately 100 µl of each diluted protein sample loaded into the ITC cell was used to determine the protein concentrations of all ITC samples, using the molar extinction coefficients of 219,500, 73,965, and 71,570 M cm−1 at 280 nm for the intact h2E2 mAb, the h2E2 Fab fragment, and the h2E2 Fc fragment, respectively. The ITC titration syringe and sample cell were extensively cleaned and washed with mild detergent and water after every run, as recommended by the instrument manufacturer. The experimental errors for the binding parameters reported in the Table are all standard deviations derived from 4 independent ITC experiments performed with each ligand.

3. Results

Isothermal titration calorimetry (ITC) was performed to analyze the thermodynamics of binding of cocaine and four cocaine metabolites to the h2E2 anti-cocaine mAb in PBS buffer at 20 °C, using appropriate concentrations of mAb and drug titrants. A summary of the results is given in Table 1, and representative ITC data and fitting of the data to a one site binding model are shown in Fig. 1 for the 3 high affinity (nM) ligands, cocaethylene (CE), cocaine (Coc), and benzoylecgonine (BE). These data are all well described by the one site binding model, with approximately one molecule of cocaine or cocaine metabolite binding per one Fab binding site present (see Fig. 1 and Table 1). The average Kd values obtained via ITC are similar, but slightly larger, to those obtained at the same temperature (20 °C) using the intrinsic tyrosine and tryptophan quenching method previously described [4], with ITC Kd values in PBS buffer of approximately 5, 8 and 54 nM for cocaethylene, cocaine, and benzoylecgonine, respectively (see Table 1), compared to approximately 1, 4, and 20 nM for cocaine, benzoylecgonine, and benzoylecgonine, respectively, using the intrinsic fluorescence quenching technique reported previously [4]. The previously published fluorescence quenching data were obtained using TBS buffer, not PBS buffer, possibly accounting for at least part of the small differences in measured affinities given by the two techniques. Also shown in Table 1 are ITC binding results obtained with 2 lower affinity cocaine metabolites, norcocaine (NC, Kd = 1400 nM) and ecgonine methyl ester (EME, Kd ≈ 19000 nM). These lower (µM) affinity ligands both have much less favorable enthalpies of binding (ΔH) than the 3 high affinity ligands, by about 5–7 fold.

### Abbreviations

- mAb: monoclonal antibody
- h2E2: humanized anti-cocaine monoclonal antibody
- Fab: fragment antigen-binding
- ITC: isothermal titration calorimetry
- PBS: phosphate buffered saline
- CE: cocaethylene
- Coc: cocaine
- BE: benzoylecgonine
- NC: norcocaine
- EME: ecgonine methyl ester
- K: binding association constant
- Kd: binding dissociation constant
- HC: antibody heavy chain
- LC: antibody light chain

### Table 1: Thermodynamic parameters for cocaine and cocaine metabolites

| Ligand   | ΔH (kJ mol⁻¹) | ΔS (J K⁻¹ mol⁻¹) | Kd (nM) |
|----------|---------------|-----------------|---------|
| Coc      |               |                 | 1400    |
| CE       |               |                 | 8       |
| BE       |               |                 | 54      |
| NC       |               |                 | 1400    |
| EME      |               |                 | 19000   |
the concentration of norcocaine in the titrating syringe, and the concentration of mAb in the ITC sample cell. As can be seen from the data that spanned different portions of the ITC binding curve, by varying \((NC)\) molecules binding to each h2E2 mAb, we analyzed norcocaine ITC lites of cocaine also have \(N\) values greater than one, i.e., more than one

In addition, unlike the high affinity ligands, these low affinity metabo-

(Table 1). However, unlike the high affinity ligands, these lower affinity ligands have positive (energetically favorable) binding entropies (\(\Delta S\)). In addition, unlike the high affinity ligands, these low affinity metabo-
lites of cocaine also have \(N\) values greater than one, i.e., more than one ligand binds for each mAb Fab site present. Thus \(N \approx 2\) for ecgonine methyl ester, and \(N \approx 3.7\) for norcocaine (Table 1).

To further investigate this unexpectedly high number of norcocaine (NC) molecules binding to each h2E2 mAb, we analyzed norcocaine ITC data that spanned different portions of the ITC binding curve, by varying the concentration of norcocaine in the titrating syringe, and the concentration of mAb in the ITC sample cell. As can be seen from the binding fitting parameters and \(N\) values for norcocaine shown in Fig. 2, the \(N\) values (and other ITC binding parameters) obtained were not dependent on the concentrations of NC or mAb used in each experiment. To confirm this and assess which part(s) of the mAb bind norcocaine, we also analyzed the intact mAb, the Fab fragment, and the Fc fragment of the mAb using the same titrating concentration of NC, and very similar concentrations of Fab sites or Fc fragments present in the ITC cell. These results, shown in Fig. 3, clearly demonstrate that norcocaine is binding only to the Fab fragment, and confirm that there are \(\approx 3.6\)–3.8 molecules of norcocaine binding to each Fab fragment of the mAb. Similar ITC experimental results were obtained using the EME metabolite, also demonstrating no EME binding to the Fc fragment (data not shown).

To further characterize the binding of cocaine and the cocaine me-
obalites that bind to the h2E2 mAb with high affinity, we also per-

4. Discussion

There are only a few published reports characterizing mAb antigen binding thermodynamics using isothermal titration calorimetry (ITC). This is likely because most antibodies recognize proteins and larger biomolecules, making binding to them less amenable to thermodynamic binding analysis by ITC. A total of only about two dozen mAb drug binding studies have utilized ITC, with several analyzing the binding of peptides to antibodies [15,16]. In addition, several studies have involved the binding of drugs by mAbs, including a methamphetamin
binding antibody [13], and a different anti-cocaine mAb than the h2E2 mAb investigated in this study, called mAb08 [14]. Despite the paucity of such studies, the determination and analysis of ligand binding thermodynamics is often important in drug discovery and drug development [17].

We have used multiple techniques to analyze and quantitate aspects of cocaine and cocaine metabolite binding to our h2E2 anti-cocaine mAb under development for the treatment of cocaine use disorders [4–8]. However, none of these methods permitted estimation or calculation of the thermodynamics of drug and drug metabolite binding to the h2E2 mAb. Therefore, we employed ITC to answer questions regarding the enthalpic vs entropic contributions of binding for cocaine and several
coco-ae-thylene (CE) and benzoylco-caine (BE)), as well as cocaine metabolites having much lower affinities than cocaine (i.e., μM affinities, including norco-caine (NC) and ece-gine methyl ester (EME)). Not surprisingly, as seen in Table 1, the binding of the high affinity binding drugs (CE, Coc, and BE) is enthalpically driven. However, the rank order of binding affinities of these high affinity drugs are partly determined by their entropic components, with CE having the highest affinity, due to a much lower negative value (less unfavorable value) for the entropy change (ΔS), when, in fact, the enthalpic component (ΔH) is slightly less favorable for CE compared to cocaine and BE, i.e., ≈14,000 cal/mol for CE, compared to ≈15,400 cal/mol for cocaine and benzoylco-caine (see Table 1). We speculate this may be explained by the ethyl ester which is added to the carboxyl group of BE to form CE leading to no additional, enthalpically favorable binding interactions with the mAb, but resulting in a less entropically unfavorable ligand (CE) ethyl ester solution/desolvation effect. This hypothesis is consistent with inspection of the h2E2 mAb BE:Fab co-crystallized structure, showing that this portion of the BE molecule, which is esterified and used to form CE, is not in contact with the mAb, sticking up from the mAb binding site [11]. Therefore, according to the BE:Fab published structure [11], the mAb binding site is not predicted to make enthalpically favorable interactions with the esterified carboxyl group present in cocaine (a methyl ester) and CE (an ethyl ester). However, the nitration of a nearby light chain tyrosine residue (LC Y34) does decrease the affinity of the mAb for CE and Coc, and not for BE, possibly indicating an additional interaction with that tyrosine might exist for CE and Coc, which is not seen in the published BE crystal. Regardless, the Kds determined by ITC for these nM affinity ligands are all similar, but slightly larger, than the Kds determined for these same ligands at the same temperature using other techniques [1,4], possibly due to differences in the experimental buffers used or in the ligand solution/desolvation effects measured by ITC but not the other methods. Nonetheless, the relative binding affinities obtained with these different techniques are similar, and the rank order of the affinities for the h2E2 anti-cocaine mAb are the same as previously determined using other techniques (Table 1).

In contrast to the high affinity drugs, the lower affinity ligands norco-caine (NC) and ece-gine methyl ester (EME), are far less enthalpically driven (i.e., have much smaller negative ΔH values), and display favorable entropic components for their binding (i.e., positive ΔS values, see Table 1). Interestingly and unexpectedly, both lower affinity cocaine metabolites also bind with a greater than 1:1 stoichiometry of binding (Table 1). This indicates a much lower negative value (less unfavorable value) for the entropy change observed for these nM affinity ligands, also being enthalpically driven for the mAb, which is similar to the binding of the high affinity drugs which are enthalpically driven.

The present ITC results utilizing our h2E2 anti-cocaine mAb are very different from those reported previously for the mAb08 anti-cocaine mAb [14], which display a similar range of affinities for Coc, CE and BE as the h2E2 mAb, but in a different rank order (Kd values for mAb08 determined by ITC for Coc, BE, and CE were 2.5, 18.6, and 34.4 nM, respectively [14]). The binding of these 3 high affinity ligands is more enthalpically driven for the mAb08 mAb than the h2E2 mAb, with ΔH values ranging from -21 to -28 kcal/mol [14], compared with -14.0 to -15.4 kcal/mol for the h2E2 mAb investigated in the present study (see Table 1). However, the ΔG values, and thus the Kds, are similar for the two antibodies, due to the much larger unfavorable entropic component of binding observed for the mAb08 antibody, i.e., -37 to -55 cal/mol/K for mAb08 [14], compared to -9.7 to -19.4 cal/mol/K for the h2E2 anti-cocaine mAb (Table 1). This indicates a very different drug binding modality for the two anti-cocaine mAbs. The crystal structure of the mAb08 mAb has not been published, but the crystal structure of the Fab fragment complexed with the cocaine metabolite, BE, has been [11]. This crystal structure indicates that the tropaeone ring is one of the central components of the mAb binding site, consistent with the present findings that loss of the single methyl group on that ring in the norco-caine metabolite greatly lowers binding affinity and completely changes the binding thermodynamics for norco-caine, as well as the stoichiometry of binding (Table 1, and Figs. 2 and 3). Unfortunately, norco-caine and ece-gine methyl ester binding were not reported for mAb08. The reason for the favorable (positive) entropic component of binding to the h2E2 mAb for the low affinity ligands, norco-caine and ece-gine methyl ester (Table 1), is not clear at present. In general, the entropic contribution to binding energies consists of three components [18]: solvent entropy changes resulting from solvent release upon binding; conformational entropy changes occurring due to changes in conformational freedom of both the protein and ligand; and entropic changes due to the loss of translational and rotational degrees of freedom following complex formation (which contributes unfavorably to the binding entropy). Thus, we speculate that it may be favorable solvent entropy changes resulting from solvent release upon binding of the low affinity ligands to multiple sites on the h2E2 mAb protein that result in the observed favorable entropic component of binding (Table 1).

Although the present ITC study does not explain on a molecular interaction level why the binding affinities for the h2E2 mAb decrease in the order of CE > Coc > BE, it does show that CE is substantially different from both cocaine and BE in its thermodynamics of binding, having a smaller unfavorable entropic binding component, and thus less “enthalpy-entropy compensation” (EEC [17,19]), which is commonly observed with the binding of many drug molecules. This enthalpy-entropy compensation decreases the favorable Gibbs free energy associated with binding, and thus the binding affinity. We hypothesize that the smaller EEC for CE, as compared to cocaine, and especially benzoylco-caine, measured for the h2E2 mAb may be due to less unfavorable solvation/desolvation entropic effects mediated due to the ethyl ester extension of the carboxylic acid of benzoylco-caine to form coco-ae-thylene.

Financial disclosure statement

Dr. Norman is named as a co-inventor on a portfolio of patents for the matter and use of the h2E2 humanized anti-cocaine monoclonal antibody.

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Andrew B. Norman has patent issued to University of Cincinnati. None.

Acknowledgments

This work was supported in part by the National Institutes of Health National Institute on Drug Abuse Grant U01DA050330. We are grateful to Catalent PharmaSolutions, Inc. (Madison, WI) for providing the recombinant humanized h2E2 anti-cocaine mAb protein expressed using their Gpex® technology. We thank Dr. Rhett Koval in the Department of Molecular Genetics, Biochemistry and Microbiology at the University of Cincinnati College of Medicine for the use of the MicroCal VP-ITC instrument, and Dr. Zhenyu Yuan in Dr. Koval’s laboratory for instruction in the use of the ITC instrument, and the fitting of the ITC data.
References

[1] H.N. Wetzel, R.P. Webster, F.O. Saeed, T.L. Kirley, W.J. Ball, A.B. Norman, Characterization of a recombinant humanized anti-cocaine monoclonal antibody produced from multiple clones for the selection of a master cell bank candidate, Biochem. Biophys. Res. commun. 487 (2017) 690–694, https://doi.org/10.1016/j.bbrc.2017.04.117.

[2] H.N. Wetzel, M.R. Tabet, W.J. Ball, A.B. Norman, The effects of a humanized recombinant anti-cocaine monoclonal antibody on the disposition of cocacethylene in mice, Int. Immunopharm. 23 (2014) 387–390, https://doi.org/10.1016/j.intimp.2014.10.025.

[3] A.B. Norman, F.C. Gooden, M.R. Tabet, W.J. Ball, A recombinant humanized anti-cocaine monoclonal antibody inhibits the distribution of cocaine to the brain in rats, Drug Metab. Dispos.: Bio. Fate Chem. 42 (2014) 1125–1131, https://doi.org/10.1124/dmd.14-057034.

[4] T.L. Kirley, A.B. Norman, Characterization of a recombinant humanized anti-cocaine monoclonal antibody and its Fab fragment, Hum. Vaccines Immunother. 11 (2015) 458–467, https://doi.org/10.4161/21645515.2014.990856.

[5] T.L. Kirley, A.B. Norman, H.N. Wetzel, A novel differential scanning fluorimetry analysis of a humanized anti-cocaine mAb and its ligand binding characteristics, J. Immunol. Methods 476 (2020), 112676, https://doi.org/10.1016/j.jim.2019.112676.

[6] T.L. Kirley, A.B. Norman, Ligand binding to a humanized anti-cocaine mAb measured by dye absorption spectroscopy, Biochem. Biophys. Res. commun. 535 (2021) 93–98, https://doi.org/10.1016/j.bbrc.2020.12.034.

[7] T.L. Kirley, A.B. Norman, Cocaine binding to the Fab fragment of a recombinant anti-cocaine mAb quantitated by dye absorption and fluorescence spectroscopy, J. Immunol. Methods 496 (2021), 113103, https://doi.org/10.1016/j.jim.2021.113103.

[8] T.L. Kirley, A.B. Norman, Ligand binding to a humanized anti-cocaine mAb detected by non-reducing SDS-PAGE, Biochem. Biophys. Res. commun. 533 (2020) 580–585, https://doi.org/10.1016/j.bbrc.2020.09.051.

[9] T.L. Kirley, A.B. Norman, K.D. Greis, Oxidation of specific tryptophan residues inhibits high-affinity binding of cocaine and its metabolites to a humanized antico cocaine mAb, J. Biol. Chem. 298 (2022), 101689, https://doi.org/10.1016/j.jbc.2022.101689.

[10] T.L. Kirley, A.B. Norman, K.D. Greis, Oxidation of specific tryptophan residues inhibits high-affinity binding of cocaine and its metabolites to a humanized antico cocaine mAb, J. Biol. Chem. 298 (2022), 101689, https://doi.org/10.1016/j.jbc.2022.101689.

[11] K. Tan, M. Zhou, A.J. Ahrendt, N.E.C. Duke, N. Tabaja, W.J. Ball, T.L. Kirley, A. B. Norman, A. Joachimiak, M. Schiffer, R. Wilton, P.R. Pokkuluri, Structural analysis of free and liganded forms of the Fab fragment of a high-affinity anti-coac eine antibody, k2E2, Acta crystallographica. Section F, Struct. Biol. Commun. 75 (2019) 697–706, https://doi.org/10.1107/S2053220319013608.

[12] T.L. Kirley, K.D. Greis, A.B. Norman, Tyrosine nitration of a humanized anti-cocaine mAb differentially affects ligand binding of cocaine and its metabolites, Biochem. Biophys. Rep. 30 (2022), 101278, https://doi.org/10.1016/j.bbrep.2022.101278.

[13] M.W. Stevens, R.L. Tawney, C.M. West, A.D. Kight, R.L. Henry, S.M. Owens, W. B. Gentry, Preclinical characteristic of an anti-methamphetamine monoclonal antibody for human use, mAbs 6 (2014) 547–555, https://doi.org/10.4161/mabs.27620.

[14] M. Ramakrishnan, F. Alves De Melo, B.M. Kinsey, J.E. Ladbury, T.R. Kosten, F. M. Orson, Probing cocaine-antibody interactions in buffer and human serum, PLoS One 7 (2012), e40518, https://doi.org/10.1371/journal.pone.0040518.

[15] M. Brockhaus, P. Ganz, W. Huber, B. Bohmann, H.R. Loetscher, J. Seelig, Thermodynamic studies on the interaction of antibodies with beta-amyloid peptide, J. Phys. Chem. B 111 (2007) 1238–1243, https://doi.org/10.1021/jp0664059.

[16] H.R. Reese, X. Xiao, C.C. Shanahan, W. Chu, G.A. Van Den Driessche, D. Fourches, R.G. Carbonell, C.K. Hall, S. Menegatti, Novel peptide ligands for antibody purification provide superior clearance of host cell protein impurities, J. Chromatogr. A 1625 (2020), 461237, https://doi.org/10.1016/j.chroma.2020.461237.

[17] S. Geschwindner, J. Ulander, P. Johannson, Ligand binding thermodynamics in drug discovery: still a hot tip? J. Med. Chem. 58 (2015) 6321–6335, https://doi.org/10.1021/jm501511l.

[18] X. Du, Y. Li, Y.L. Xia, S.M. Ai, J. Liang, P. Sang, X.L. Ji, S.Q. Liu, Insights into protein-ligand interactions: mechanisms, models, and methods, Int. J. Mol. Sci. 17 (2016), https://doi.org/10.3390/ijms17020144.

[19] R. Lumry, S. Rajender, Enthalpy-entropy compensation phenomena in water solutions of proteins and small molecules: a ubiquitous property of water, Biopolymers 9 (1970) 1125–1227, https://doi.org/10.1002/bip.1970.360091002.